KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elanco Animal Health (ELAN) EBITDA (2017 - 2025)

Elanco Animal Health (ELAN) has disclosed EBITDA for 9 consecutive years, with $158.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 128.62% to $158.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $795.0 million through Dec 2025, up 152.48% year-over-year, with the annual reading at $795.0 million for FY2025, 152.48% up from the prior year.
  • EBITDA hit $158.0 million in Q4 2025 for Elanco Animal Health, down from $167.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $249.0 million in Q1 2025 to a low of -$1.6 billion in Q3 2023.
  • Historically, EBITDA has averaged -$426.6 million across 5 years, with a median of -$514.5 million in 2022.
  • Biggest five-year swings in EBITDA: crashed 206.98% in 2023 and later skyrocketed 149.5% in 2025.
  • Year by year, EBITDA stood at -$635.0 million in 2021, then increased by 15.43% to -$537.0 million in 2022, then decreased by 19.74% to -$643.0 million in 2023, then grew by 14.15% to -$552.0 million in 2024, then soared by 128.62% to $158.0 million in 2025.
  • Business Quant data shows EBITDA for ELAN at $158.0 million in Q4 2025, $167.0 million in Q3 2025, and $221.0 million in Q2 2025.